NRG Energy Inc (NRG) Stock Price Today
Aura AI Summary
Key Stats
- $18.44BMarket Cap
- 4,955,287Volume
- UtilitiesSector
- $184.0352W High
- $80.5552W Low
- 66 DaysTypical Hold Time
- $42.07BEnterprise Value
- 2.16%Div Yield
- -Trading Activity
Track NRG Energy Inc (NRG) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, NRG Energy Inc has traded between a low of $80.55 and a high of $184.03, highlighting its annual price range. Buy and sell NRG Energy Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Most Recent News
Home Depot and Lowe's see declining sales amid high mortgage rates and weak housing market.
Home Depot and Lowe's reported declines in comparable transactions in Q3 2026 due to a sluggish housing market and rising mortgage rates now above 7%. This has led to fewer home sales and softer demand for home improvement projects, as consumers dela...

Tesla's Cybercab launch signals robotaxi growth in 2027, urging caution on a SpaceX merger before success.
Tesla has started selling Cybercabs, priced at $29,990 with a $299 monthly subscription, but their current use is limited to specific areas and lacks manual controls. This launch is mainly promotional, highlighting Tesla's focus on becoming a transpo...

FDA approval for Grail's Galleri cancer test expected in early 2027, key for insurer coverage and pricing.
Grail expects FDA approval for its multi-cancer early detection test, Galleri, in Q1 2027, which could lead to Medicare and commercial insurer coverage. Despite a failed primary endpoint in a large NHS trial, Galleri showed promising results for 12 d...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.